Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors

TAK‐931, a novel, selective, small‐molecule inhibitor of cell division cycle 7 has been investigated in multiple clinical trials in patients with advanced solid tumors. An integrated analysis using data from 2 clinical studies assessed effects of TAK‐931 on electrocardiogram QT intervals and heart r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Diderichsen, Paul Matthias, Gupta, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306994/
https://www.ncbi.nlm.nih.gov/pubmed/35187855
http://dx.doi.org/10.1002/cpdd.1075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306994/
https://www.ncbi.nlm.nih.gov/pubmed/35187855
http://dx.doi.org/10.1002/cpdd.1075

Ejemplares similares